Processa Pharmaceuticals, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is a clinical-stage biopharmaceutical company focused on developing Next Generation Chemotherapy (NGC) oncology drugs that modify the metabolism, distribution, or elimination of existing FDA-approved cancer therapies to improve safety and efficacy while preserving their mechanisms of action; its lead product candidates include PCS6422 (NGC-Cap), a combination with capecitabine in Phase 2 trials for metastatic colorectal, gastrointestinal, breast, pancreatic, and other solid tumors; PCS3117 (NGC-Gemcitabine), which has completed Phase 2a trials for pancreatic, biliary tract, lung, ovarian, breast, and other cancers; and PCS11T (NGC-Irinotecan), a preclinical asset for lung, colorectal, gastrointestinal, pancreatic, and other cancers. The company also maintains non-oncology assets such as PCS12852 in Phase 2B trials for gastroparesis and related gastrointestinal motility disorders, and PCS499 for glomerular disease. Founded in 2017 and headquartered in Hanover, Maryland, Processa operates primarily in the United States with license agreements including Elion Oncology, Inc., Ocuphire Pharma, Inc., Aposense, Ltd., Yuhan Corporation, and CoNCERT Pharmaceuticals, Inc. Recent developments include securing a strategic investment in August 2025 to bolster financial stability and exploring corporate cryptocurrency treasury strategies with LifeSci Capital, LLC to diversify capital and fund clinical programs; entering a binding term sheet in 2025 with Intact Therapeutics, Inc. for an exclusive option to license PCS12852, potentially yielding up to $454 million in milestones, 12% royalties, and a 3.5% equity stake; and establishing a dedicated subsidiary for PCS499 to enhance partnership and capital-raising flexibility following FDA interactions.
Reviewing Stevanato Group (NYSE:STVN) and Heatwurx (NASDAQ:PCSA)
Heatwurx (NASDAQ:PCSA) versus Aquestive Therapeutics (NASDAQ:AQST) Critical Review
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study
Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
Processa Pharmaceuticals Provides Portfolio and Business Update
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering
Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate
Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting
Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference
Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer